Fresenius Medical Care

Sanford C. Bernstein 8 th Annual Strategic Decisions Conference London, September 20, 2011

Safe Harbor Statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Q2 | Dialysis Services Global

	Clinics	Patients	Treatments (in millions)
Total	2,838	225,909	16.5
Growth vs. June 30, 2010	+ 10%	+ 12%	+ 9%
North America	1,826	139,906	10.6
Growth vs. June 30, 2010	+ 2%	+ 4%	+ 4%
International	1,012	86,003	5.9
Europe	569	45,997	2.9
Latin America	200	23,163	1.8
Asia-Pacific	243	16,843	1.2

North America Latin America EMEA Asia Pacific World Leader in Dialysis Services¹ •We lead in every major market, treating more than 225,909 patients worldwide – # of patients 13,500 131,000 139,906 3,400 8,600 23,163 13,900 18,500 45,997 4,500 5,000 21,343² FME DaVita Dialysis Clinic Inc. FME Baxter Diaverum FME KfH Diaverum FME Showai-Kai Zenji-Kai ¹ Based on company statements and estimates ² Patients including managed clinics (4,500 patients AP) ³ U.S. market share 34% FME's market share 28%³ 11% 8% 3%

Market Position by Major Product Groups 2010

Rank 1	Rank 2
FME	Gambro
FME	Gambro
FME	Fuso
FME	Gambro
Baxter	FME

2011 Sales and earning outlook confirmed
Another record year to be expected
For 2011 strong revenue growth and further earnings momentum expected
\$ in m	FY 2011
Net revenue	> 13,000
Net income attributable to FMC AG & Co. KGaA	1,070 – 1,090
Capital expenditure in % of revenue	~ 5%
Acquisitions	~ 1,900
Leverage ratio (Debt/EBITDA ratio)	< 3.0

2010│2011 Product Launches

Vertical Integrated Care Provider

Global Footprint

Dialysis clinics
North America: 1,826 clinics
Europe: 569 clinics
Asia-Pacific: 295 clinics¹
Latin America: 200 clinics

Headquarters

Buzen Japan

Inukai Japan

Major Production Sites